Multiple Myeloma in Italy: An Epidemiological Model by Treatment Line and Refractoriness Status
Our model revealed a rising prevalence of patients receiving first-line treatment owing to more effective treatments. The marked increase in the number of refractory patients in subsequent lines underscores the urgent need for innovative therapies to address treatment resistance.
Authors
- Roberto Mina (ORCID: https://orcid.org/0000-0002-8144-541X)
- Gianni Ghetti (ORCID: https://orcid.org/0000-0001-6809-5251)
- Silvia Mangiacavalli (ORCID: https://orcid.org/0000-0001-9787-3083)
- Fabrizio Iannello
- Stefania Bellucci
- Bernardo Rossini
- Simona Pellizzaro
Institutions
- Johnson & Johnson (United States) (US)
- University of Pavia (IT)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Istituto Tumori Bari (IT)
- Johnson & Johnson (Italy) (IT)
- Adresseavisen (Norway) (NO)
- Policlinico San Matteo Fondazione (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- Clinical Lymphoma Myeloma & Leukemia
- Published
- 2024-12-24
- DOI
- https://doi.org/10.1016/j.clml.2024.12.012
- Citations
- 3
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.36